Stock Performance Overview
On 4 March 2026, Bharat Immunological & Biological Corporation Ltd’s stock price touched Rs.15.8, the lowest level recorded in the past 52 weeks. This represents a decline of over 45% from its 52-week high of Rs.28.8. Despite outperforming its sector by 2.96% on the day of the new low, the stock remains well below key moving averages, trading beneath its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This technical positioning indicates sustained downward momentum.
The broader market context saw the Sensex open sharply lower by 1,710.03 points but recover partially to close at 78,731.58, down 1.88%. While the Sensex itself trades below its 50-day moving average, the 50DMA remains above the 200DMA, signalling mixed market conditions. Notably, other indices such as NIFTY Realty and S&P BSE Realty also hit new 52-week lows on the same day, underscoring sectoral volatility.
Financial and Operational Metrics
Bharat Immunological & Biological Corporation Ltd’s financial health continues to raise concerns. The company has not declared any results in the last six months, contributing to uncertainty around its current standing. Its Mojo Score stands at 3.0 with a Mojo Grade of Strong Sell, an upgrade from Sell on 9 April 2024, reflecting deteriorating fundamentals.
Over the past five years, the company’s net sales have contracted at an annualised rate of -24.67%, while operating profit has declined sharply by -170.32%. The latest nine-month net sales figure of ₹76.5 million represents a steep year-on-year decline of -87.03%. Operating cash flow for the year has dropped to its lowest level at ₹0 million, indicating limited liquidity generation from core activities.
The company’s debt metrics also highlight financial strain. The debt-to-equity ratio reached a high of 83.16% in the half-year period, while the Debt to EBITDA ratio stands at -1.00 times, signalling challenges in servicing debt obligations. These factors contribute to the stock’s classification as risky relative to its historical valuation averages.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Comparative Performance and Market Position
In the last twelve months, Bharat Immunological & Biological Corporation Ltd’s stock has generated a negative return of -21.56%, significantly underperforming the Sensex, which posted a positive return of 7.88% over the same period. The stock has also lagged behind the BSE500 index across multiple time frames including the last three years, one year, and three months.
The company’s market capitalisation grade is rated 4, indicating a relatively modest market cap within its sector. Despite the stock’s recent outperformance relative to its sector on the day of the new low, the overall trend remains downward, reflecting persistent challenges in regaining investor confidence.
Recent Quarterly and Half-Year Data
Negative results reported in September 2023 further illustrate the company’s difficulties. The nine-month net sales figure of ₹76.5 million declined by 87.03% year-on-year, while operating cash flow for the year was reported at zero. The half-year debt-to-equity ratio peaked at 83.16%, underscoring the company’s elevated leverage position.
Profitability has also been under pressure, with profits falling by 42.4% over the past year. These financial indicators contribute to the stock’s Strong Sell rating and reflect the company’s subdued growth prospects in the current environment.
Holding Bharat Immunological & Biological Corporation Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Technical Indicators and Market Sentiment
The stock’s position below all major moving averages signals a bearish technical outlook. Trading below the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages suggests sustained selling pressure and limited short-term momentum. This technical weakness aligns with the company’s fundamental challenges and recent financial disclosures.
While the broader market has shown some recovery from initial declines, the Pharmaceuticals & Biotechnology sector remains volatile, with several stocks including Bharat Immunological & Biological Corporation Ltd experiencing significant price corrections. The stock’s current valuation and performance metrics reflect the market’s cautious stance towards the company’s near-term prospects.
Summary of Key Metrics
To summarise, Bharat Immunological & Biological Corporation Ltd’s stock has reached a 52-week low of Rs.15.8, down from a high of Rs.28.8. The company’s Mojo Grade stands at Strong Sell with a score of 3.0, reflecting weak long-term fundamentals and deteriorating financial health. Net sales and operating profits have contracted sharply over the last five years, while debt levels remain elevated. The stock’s underperformance relative to the Sensex and BSE500 indices further highlights the challenges faced by the company in the current market environment.
These factors collectively explain the stock’s recent decline and its position at a new 52-week low, underscoring the ongoing pressures within Bharat Immunological & Biological Corporation Ltd’s business and market valuation.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
